 ROCKVILLE, MD, Jan. 11, 2021 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Companys management will participate in the following investor conferences in January: 